CORCEPT THERAPEUTICS INC CORT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
8.97
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $761.4M | $99.7M | — | $141.8M | $647.8M |
| 2024 | $675.0M | $141.2M | — | $196.1M | $679.6M |
| 2023 | $482.4M | $106.1M | — | $126.5M | $506.7M |
| 2022 | $401.9M | $101.4M | — | $119.9M | $501.8M |
| 2021 | $366.0M | $112.5M | — | $167.4M | $375.8M |
| 2020 | $353.9M | $106.0M | — | $150.7M | $523.3M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.97 (safe)
- Working capital / assets 0.382
- Retained earnings / assets 0.769
- EBIT / assets 0.054
- Equity / liabilities 3.43
Source: SEC EDGAR filings · CIK 0001088856 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.